Congress Demands Rescheduling Answers from DOJ: Where's the Timeline?
Advertisement
Table of Contents
- The Plot Thickens: Congress Is Getting Impatient
- What's Actually Supposed to Happen?
- The Timeline That's Not Really a Timeline
- What This Means for the Cannabis Industry Right Now
- Why Congress Is Losing Patience
- The Bigger Picture: What Happens Next?
- The Real Test: Can the Government Actually Move Fast?
- The Bottom Line
The Plot Thickens: Congress Is Getting Impatient
Picture this: it's March 30, 2026, and Rep. Steve Cohen from Tennessee is sitting down to write a strongly-worded letter to Attorney General Pam Bondi and DEA Administrator Terrance Cole. The subject?
"Where the heck is our cannabis rescheduling [Quick Definition: The federal process of moving cannabis from Schedule I to a less restrictive category]?" (okay, maybe not in those exact words, but the vibe was definitely there).
Here's the situation: nearly three months have passed since President Trump issued his executive order in December 2025 directing the Department of Justice to expeditiously reschedule cannabis from Schedule I to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone]. Sounds good, right? Executive order, expeditious action, timeline established.
Except... nothing. Or at least, nothing publicly announced, nothing finalized, and definitely nothing that looks like it's moving fast enough for Congress.
The cannabis industry has been on this rollercoaster for years now. First came Biden's 2024 proposed rulemaking in May. Then Trump takes office, says "let's speed this up," and here we are three months later still waiting for actual movement.
Meanwhile, researchers can't access the product they need, patients are still fighting for access in many states, and the entire legal cannabis market is stuck in this weird purgatory where something is federally illegal but also... kind of legal depending on where you are? It's a mess.
What's Actually Supposed to Happen?
Before we get into the weeds (pun intended), let's understand what Schedule III actually means and why Congress is sending letters instead of just chill-axing.
Under current federal law, cannabis sits on Schedule I, which is the most restrictive classification. Schedule I drugs supposedly have:
- High potential for abuse
- No currently accepted medical use
- A lack of accepted safety for use under medical supervision
Schedule III, meanwhile, includes drugs like ketamine and some anabolic steroids. It's still controlled, but it opens doors. Moving cannabis from Schedule I to Schedule III would:
- Allow easier research – The FDA could actually fund and approve cannabis research without jumping through impossible hoops
- Create banking options – Financial institutions could theoretically work with cannabis businesses without fear of federal prosecution
- Reduce penalties – Criminal consequences would be less severe
- Enable medical recognition – Create a pathway for FDA approval of cannabis-derived medicines
But here's the catch: it's not automatic. Rescheduling requires federal rule-making. There's a process.
And that process takes time. Even expeditious rescheduling isn't fast-track.
The Timeline That's Not Really a Timeline
Let's trace the bureaucratic journey:
May 2024: Under the Biden administration, HHS recommends rescheduling to Schedule III. The DEA opens a public comment period. Cannabis advocates, researchers, and patients rejoice.
This is it, they think. This is the moment.
December 2025: Trump takes office and, in a move that surprised literally everyone, doubles down on rescheduling. His executive order tells the DOJ to make it happen "expeditiously." Cool. Expeditious is... expeditious, right?
March 2026: Rep. Cohen writes a letter saying, "Hey, it's been three months. Where's the update?" The DOJ missed a deadline for easing Schedule I research barriers, which was apparently supposed to happen already.
Congress wants answers. Congress is not happy.
The problem? Nobody outside the DOJ really knows how long this actually takes. The federal rule-making process is intentionally designed to be careful and thorough.
There's notice-and-comment periods, legal review, coordination between multiple agencies, and more bureaucratic checkpoints than you can shake a hemp joint at.
What This Means for the Cannabis Industry Right Now
Here's where it gets real. The cannabis market has been operating in this legal gray zone for over a decade in some states. Businesses have been built, jobs have been created, and billions of dollars have changed hands—all while cannabis technically remains a Schedule I substance.
Rescheduling to Schedule III doesn't suddenly make cannabis federally legal or create some magical nationwide market. But it does change the game in crucial ways:
For Researchers: Universities and private researchers could actually study cannabis with reasonable ease. Right now, DEA licensing for cannabis research is so restrictive that most major universities avoid it. Schedule III would open up legitimate scientific inquiry, which could lead to actual medical breakthroughs instead of just anecdotal evidence and forward-thinking startups.
For Businesses: Even if dispensaries stay primarily state-regulated, rescheduling would allow cannabis businesses to access normal banking services, negotiate with insurance companies, and operate with significantly reduced federal risk. That's not small potatoes. Right now, many cannabis businesses operate on cash because banks won't touch them.
Rescheduling changes that calculus.
For Patients: A lot of patients in non-legal states are SOL right now. Some of them are suffering from conditions that cannabis could genuinely help. Rescheduling doesn't make everything legal nationwide, but it creates an opening for federal recognition of cannabis as medicine, which could lead to more states reconsidering their own laws.
For States: Rescheduling doesn't override state bans (see: Idaho, still holding strong in 2026), but it removes the federal threat hanging over legal cannabis operations in compliant states. That's huge for regulatory certainty and industry growth.
Why Congress Is Losing Patience
Here's the thing about Congress: they're not exactly known for their speed either. But when Congress gets impatient, you know something's not moving fast enough.
Rep. Cohen's letter signals frustration from lawmakers who want to see action. They gave the administration a directive (sort of—the executive order is from Trump, not Congress).
They've been patient through procedural requirements. And now they want accountability.
The DOJ probably has legitimate reasons for the delay. Federal agencies are massive, bureaucratic entities. The DEA has stakeholders to consider.
There might be legal complexities we don't see. Maybe they're dotting every i and crossing every t to make sure this sticks legally.
But from the outside, it looks like: executive order issued in December, three months pass, and nobody has much to show for it. Congress is asking reasonable questions: What's the timeline? What are the barriers?
When should we expect a decision?
The Bigger Picture: What Happens Next?
If we're being honest, here's what probably happens:
Best case: The DOJ responds to Congress's pressure, accelerates the process, and rescheduling happens sometime in 2026. We're talking maybe another 3-6 months of formal rule-making after the DEA and DOJ finalize their position.
Realistic case: There's negotiation, back-and-forth with Congress, maybe some hearings. The process grinds forward. Rescheduling happens by late 2026 or early 2027.
Worst case: Litigation. Advocacy groups sue. The process gets tied up.
We're looking at a years-long fight again.
The cannabis industry has seen all three scenarios before. They're not exactly waiting around passively anymore either. Advocacy groups are mobilizing, businesses are hiring lobbyists, and patients are making their voices heard.
The Real Test: Can the Government Actually Move Fast?
Here's what Congress is really testing: can the federal government actually move with urgency on cannabis policy? For decades, the answer has been a resounding "no." But now, with bipartisan interest in cannabis policy reform (yes, it's surprisingly bipartisan these days), executive backing, and mounting industry pressure, maybe things are different.
Rep. Cohen's letter is a friendly reminder that Congress is watching. That matters.
It creates political pressure. It forces the DOJ to stay focused on the issue instead of letting it get buried under other priorities.
Will it work? Probably. Eventually.
But "eventually" in federal government time means... we'll find out in a few more months.
The Bottom Line
Congress wants answers. The DOJ needs to provide them. The cannabis industry is waiting.
And somewhere in a congressional office, Rep. Cohen is probably drafting a follow-up letter.
The March 30, 2026 reality is this: we're closer to federal cannabis rescheduling than we've ever been. An executive order exists. Congressional pressure is building.
The process is moving—just not as fast as anyone would like.
In the meantime, the legal cannabis market keeps humming along in the states that have embraced it. Patients keep using it. Researchers keep pushing for access.
And Congress keeps asking the DOJ, "Um, guys? When?"
The answer should come soon. Should. We'll see.
Pull-Quote Suggestions:
"Businesses have been built, jobs have been created, and billions of dollars have changed hands—all while cannabis technically remains a Schedule I substance."
"Right now, many cannabis businesses operate on cash because banks won't touch them."
"Picture this: it's March 30, 2026, and Rep."
Why It Matters: Rep. Steve Cohen pressures AG Bondi on cannabis rescheduling. Trump's executive order deadline missed. What comes next?